Table of Contents
What are the new oral anticoagulant?
In the last few years, FDA has approved three new oral anticoagulant drugs – Pradaxa (dabigatran), Xarelto (rivaroxaban), and Eliquis (apixaban). Like warfarin, all three are ‘blood thinners’ that reduce the overall risk of stroke related to atrial fibrillation but they also cause bleeding.
What are the indications for anticoagulants?
Anticoagulants are recommended in patients predisposed to deep vein thrombosis, pulmonary embolism and stroke as well as in patients who have already developed these conditions to prevent further progression. Unstable angina and heart attack – A patient may develop chest pain due to blockage to the flow of blood.
Which anticoagulant is indicated for oral administration?
Direct oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular contexts.
What are NOACs used for?
What are NOACs and who are they recommended for? The novel oral anticoagulants (NOACs) are a new class of anticoagulant drug. They can be used in the prevention of stroke for people with non-valvular AF, which is when AF is not associated with a problem in a heart valve.
When do you use DOAC vs warfarin?
In general, the DOACs are safer and more effective than warfarin, especially when it comes to serious bleeding. DOACs cause half as much life-threatening bleeding than warfarin. They’re also more convenient than warfarin because they don’t require frequent blood monitoring and can be given safely in fixed doses.
How do newer oral anticoagulants differ from warfarin?
New oral anticoagulants (NOAC) are the latest addition to anticoagulant armamentarium. Unlike traditional anti-coagulants like warfarin, lab monitoring and management of bleeding complications secondary to these agents is different.
Which is better dabigatran or rivaroxaban?
Conclusions— In this systematic review and meta-analysis, rivaroxaban was as effective as dabigatran, but was more effective than warfarin for the prevention of stroke/thromboembolism in atrial fibrillation patients.
Why is apixaban better than dabigatran?
Apixaban had significantly lower rates of major bleeding in all comparisons, except when compared with dabigatran in patients with a CHA2DS2- VASc of 2 or 3. No significant interaction between treatment and baseline stroke or bleeding risks was found (Fig 4).